Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

ailex pharmaceuticals, llc - sodium phenylacetate (unii: 48n6u1781g) (phenylacetic acid - unii:er5i1w795a), sodium benzoate (unii: oj245fe5eu) (benzoic acid - unii:8skn0b0mim) - sodium phenylacetate 100 mg in 1 ml - sodium phenylacetate and sodium benzoate injection, 10%/10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. during acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see warnings and precautions (5) ]. none. pregnancy category c. animal reproduction studies have not been conducted with sodium phenylacetate and sodium benzoate injection, 10%/10%. it is not known whether sodium phenylacetate and sodium benzoate injection, 10%/10% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. thus, sodium phenylacetate and sodium benzoate injection, 10%/10% should be given to a pregnant woman only if clearly needed. it is not known whether sodium phenylacetate, sodium benzoate, or their conjugation p

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - glucose, quantity: 12.5 g - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - the solutions are indicated for intravenous fluid therapy designed to correct deficiencies in energy levels. glucose 5% is also used to correct hydration levels. the solutions may also be used as solvents for intravenously administered drugs where compatibility has been established.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - glucose, quantity: 5 g - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - the solutions are indicated for intravenous fluid therapy designed to correct deficiencies in energy levels. glucose 5% is also used to correct hydration levels. the solutions may also be used as solvents for intravenously administered drugs where compatibility has been established.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - glucose, quantity: 2.5 g - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - the solutions are indicated for intravenous fluid therapy designed to correct deficiencies in energy levels. glucose 5% is also used to correct hydration levels. the solutions may also be used as solvents for intravenously administered drugs where compatibility has been established.

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 6.5mmol) effervescent tablets bpc 1968 (actavis uk ltd - potassium bicarbonate; potassium acid tartrate - effervescent tablet - 500mg ; 300mg

Իսրայել - անգլերեն - Ministry of Health

lapidot medical import and marketing ltd - glucose as monohydrate - concentrate for solution for infusion - glucose as monohydrate 50 % - glucose - glucose - high caloric carbohydrate infusion hypoglycaemia.

Իսրայել - անգլերեն - Ministry of Health

lapidot medical import and marketing ltd - glucose as monohydrate - solution for infusion - glucose as monohydrate 20 % - glucose - glucose - high caloric carbohydrate infusion hypoglycaemia.

Իսրայել - անգլերեն - Ministry of Health

lapidot medical import and marketing ltd - potassium chloride - concentrate for solution for infusion - potassium chloride 14.9 g / 100 ml - potassium chloride - potassium chloride - treatment of potassium deficiency states when oral replacement is not feasable.

Իսրայել - անգլերեն - Ministry of Health

lapidot medical import and marketing ltd - glucose as monohydrate - solution for infusion - glucose as monohydrate 10 % - glucose - glucose - carbohydrate infusion therapy : - hypoglycaemic situations, - hypertonic dehydration , - hypertonic electrolyte disturbances. vehicle solution for supplementary medication.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

hospira, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid, unspecified form - unii:33x04xa5at), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0 - potassium chloride 1.79 g in 1000 ml - these solutions are indicated in patients requiring parenteral administration of potassium chloride and the replacement of extracellular losses of fluids and electrolytes with minimal carbohydrate calories. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. solutions containing lactate are not for use in the treatment of lactic acidosis. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw need